142 related articles for article (PubMed ID: 29165406)
1. [The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy].
Khoroshilova-Maslova IP; Leparskaya NL; Vorotelyak EA; Vasiliev AV
Vestn Oftalmol; 2017; 133(5):4-10. PubMed ID: 29165406
[TBL] [Abstract][Full Text] [Related]
2. Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells.
Wong CA; Potter MJ; Cui JZ; Chang TS; Ma P; Maberley AL; Ross WH; White VA; Samad A; Jia W; Hornan D; Matsubara JA
Can J Ophthalmol; 2002 Jun; 37(4):211-20. PubMed ID: 12095094
[TBL] [Abstract][Full Text] [Related]
3. Experimental Modeling of Proliferative Vitreoretinopathy. An Experimental Morphological Study.
Khoroshilova-Maslova IP; Leparskaya NL; Nabieva MM; Andreeva LD
Bull Exp Biol Med; 2015 May; 159(1):100-2. PubMed ID: 26033599
[TBL] [Abstract][Full Text] [Related]
4. [Melfalan in the treatment of proliferative vitreoretinopathy (experimental study)].
Khoroshilova-Maslova IP; Leparskaya NL; Alpeeva EV; Voroteliak EA
Vestn Oftalmol; 2020; 136(4):19-25. PubMed ID: 32779453
[TBL] [Abstract][Full Text] [Related]
5. [Experimental morphological study of posttraumatic proliferative vitreoretinopathy prevention by cell adhesion peptide Arg-Gly-Asp-Ser].
Khoroshilova-Maslova IP; Babizhaev MA; Kiseleva OA; Ilatovskaia LV
Vestn Oftalmol; 1997; 113(4):27-31. PubMed ID: 9381638
[TBL] [Abstract][Full Text] [Related]
6. Proliferative vitreoretinopathy in the Swine-a new model.
Umazume K; Barak Y; McDonald K; Liu L; Kaplan HJ; Tamiya S
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4910-6. PubMed ID: 22729438
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits.
Yu HG; Chung H
Korean J Ophthalmol; 1997 Dec; 11(2):98-105. PubMed ID: 9510652
[TBL] [Abstract][Full Text] [Related]
8. [Alterations in the structure of the epiretinal membranes in PVR -- assumptions and reality].
Vidinova C; Voinov L; Vidinov N
Klin Monbl Augenheilkd; 2005 Jul; 222(7):568-71. PubMed ID: 16034724
[TBL] [Abstract][Full Text] [Related]
9. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy.
Tahara YR; Sakamoto TR; Oshima YR; Ishibashi TR; Inomata HR; Murata TR; Hinton DR; Ryan SJ
Curr Eye Res; 1999 Oct; 19(4):323-9. PubMed ID: 10520228
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of suicide gene. Can proliferative vitreoretinopathy be a target of gene therapy?
Sakamoto T; Kimura H; Scuric Z; Spee C; Gordon EM; Hinton DR; Anderson WF; Ryan SJ
Ophthalmology; 1995 Oct; 102(10):1417-24. PubMed ID: 9097787
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of experimental proliferative vitreoretinopathy in rabbits].
Kuriyama S; Ohuchi T; Okada M; Yamakawa R; Yoshimura N; Honda Y
Nippon Ganka Gakkai Zasshi; 1990 Sep; 94(9):792-8. PubMed ID: 2248164
[TBL] [Abstract][Full Text] [Related]
12. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR
Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injection of fibroblasts: the pathological effects on the ocular tissues of the rabbit following an intravitreal injection of autologous skin fibroblasts.
Hitchins CA; Grierson I
Br J Ophthalmol; 1988 Jul; 72(7):498-510. PubMed ID: 3415942
[TBL] [Abstract][Full Text] [Related]
14. Effect of different fixative solutions on eyes with experimental proliferative vitreoretinopathy.
Nassar K; Lüke J; Lüke M; Kamal M; Soliman MM; Grisanti S; Grisanti S
Int J Exp Pathol; 2015 Apr; 96(2):103-10. PubMed ID: 25670226
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Tissue Plasminogen Activator Injection for the Treatment of Proliferative Vitreoretinopathy in a Rabbit Model.
Reitblat O; Barayev E; Gal-Or O; Tsessler M; Dotan A
Ophthalmic Res; 2023; 66(1):48-56. PubMed ID: 35772382
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.
Khanum BNMK; Guha R; Sur VP; Nandi S; Basak SK; Konar A; Hazra S
Eye (Lond); 2017 Sep; 31(9):1317-1328. PubMed ID: 28304388
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells.
Casaroli-Marano RP; Pagan R; Vilaró S
Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2062-72. PubMed ID: 10440262
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive circular RNA profiling of proliferative vitreoretinopathy and its clinical significance.
Yao J; Hu LL; Li XM; Shan K; Zhou RM; Ge HM; Yao MD; Jiang Q; Zhao C; Yan B
Biomed Pharmacother; 2019 Mar; 111():548-554. PubMed ID: 30597308
[TBL] [Abstract][Full Text] [Related]
20. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
